3-溴吡啶-2-甲醛 | 405174-97-2

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-溴吡啶-2-甲醛
• 中文别名: 3-溴-2-甲酰基吡啶；3-溴-2-吡啶甲醛
• 英文名称: 3-bromopicolinaldehyde
• 英文别名: 3-bromopyridine-2-carbaldehyde；3-bromo-2-formylpyridine；3-bromopyridine-2-carboxaldehyde；3-bromo-2-pyridinecarboxaldehyde
• CAS: 405174-97-2
• 化学式: C₆H₄BrNO
• 分子量: 186.008
• InChiKey: DCOPXKMVVJNPSW-UHFFFAOYSA-N

物化性质

• 沸点：
  223.0±20.0 °C(Predicted)
• 密度：
  1.683±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Bromopyridine-2-carboxaldehyde
Synonyms: 3-Bromo-2-formylpyridine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Bromopyridine-2-carboxaldehyde
CAS number: 405174-97-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H4BrNO
Molecular weight: 186.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-溴吡啶-2-甲醛 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 potassium fluoride dihydrate 、 potassium carbonate 、 三乙胺 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 16.5h， 生成 (1E,4E)-1,5-bis(3-ethynylpyridin-2-yl)penta-1,4-dien-3-one
  参考文献：
  名称：

  Synthesis of the pyridinyl analogues of dibenzylideneacetone (pyr-dba) via an improved Claisen–Schmidt condensation, displaying diverse biological activities as curcumin analogues

  摘要：

  在甲苯-EtOH-H2O 溶剂体系中，在 K2CO3 的存在下，通过取代的烟醛和丙酮的缩合，开发了一种合成二亚苄基丙酮（pyr-dba）吡啶类似物的高效简便的方法。用这种方法可以在温和的条件下方便地制备出结构多样的吡咯-二巴（包括喹啉基二巴），收率从中等到极好。所制备的 pyr-dba 可作为姜黄素的烯酮类似物，有效抑制 NF-κB 的活化、结直肠癌 HCT116 p53+/+ 细胞的生长以及 HIV-1 IN-LEDGF/p75 的相互作用。

  DOI：

  10.1039/c1ob06773g
• 作为产物：
  描述：

  3-溴-2-吡啶羧酸 在 草酰氯 、 N,N-二甲基甲酰胺 、 甲醇 、 二异丁基氢化铝 作用下， 以 二氯甲烷 、 四氢呋喃 为溶剂， 反应 7.0h， 生成 3-溴吡啶-2-甲醛
  参考文献：
  名称：

  HIV-1 CA 靶向小分子的设计、合成和表征：PF74 的构象限制

  摘要：

  靶向 HIV-1 衣壳蛋白 (CA) 的 PF74 结合位点的小分子具有强大且机械独特的抗病毒活性。PF74 的结构修饰可以进一步了解配体结合模式，使配体化学类别多样化，并允许鉴定具有平衡抗病毒活性和代谢稳定性的新变体。在目前的工作中，我们设计并合成了三个系列的 PF74 样类似物，在苯胺末端或苯丙氨酸甲酰胺部分具有构象限制，并使用生物物理热位移测定 (TSA)、基于细胞的抗病毒和细胞毒性测定对其进行表征，以及在人和小鼠肝微粒体中的体外代谢稳定性测定。这些研究表明，苯丙氨酸甲酰胺部分被吡啶或咪唑环取代的两个系列可以提供可行的命中。随后的 SAR 确定了改进的模拟15有效抑制 HIV-1 (EC 50 = 0.31 μM)，强烈稳定 CA 六聚体 (ΔTm = 8.7 °C)，并表现出显着增强的代谢稳定性（t 1/2 = 27 min for 15 vs. 0.7 min for PF74）

  DOI：

  10.3390/v13030479

文献信息

• [EN] METHYL OXAZOLE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] MÉTHYLOXAZOLES ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016089721A1

  公开（公告）日：2016-06-09

  The present invention is directed to methyl oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及甲基噁唑化合物，其为促进睡眠的受体拮抗剂。本发明还涉及所述化合物在潜在治疗或预防涉及促进睡眠的神经和精神疾病和疾病中的用途。本发明还涉及包含这些化合物的组合物。本发明还涉及这些组合物在潜在预防或治疗涉及促进睡眠的疾病中的用途。
• [EN] 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS<br/>[FR] 1H-PYRAZOLO [4,3-B] PYRIDINES EN TANT QU'INHIBITEURS DE PDE1
  申请人：H LUNDBECK AS

  公开号：WO2018007249A1

  公开（公告）日：2018-01-11

  The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

  本发明提供了式(I)的1H-吡唑并[4,3-b]吡啶-7-胺作为PDE1抑制剂，并将其用作药物，特别用于治疗神经退行性疾病和精神疾病。
• 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS
  申请人：H. Lundbeck A/S

  公开号：US20190194189A1

  公开（公告）日：2019-06-27

  The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

  本发明提供了式(I)的1H-吡唑并[4,3-b]吡啶类化合物作为PDE1抑制剂，并将其用作药物，特别用于治疗神经退行性疾病和精神疾病。
• MTA-Cooperative PRMT5 Inhibitors
  申请人：Mirati Therapeutics, Inc.

  公开号：US20210078994A1

  公开（公告）日：2021-03-18

  The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

  本发明涉及抑制蛋白精氨酸N-甲基转移酶5（PRMT5）活性的化合物。具体而言，本发明涉及化合物、药物组合物和使用方法，例如使用本发明的化合物和药物组合物治疗癌症的方法。
• Cobalt-catalyzed asymmetric hydrogenation of ketones: A remarkable additive effect on enantioselectivity
  作者：Tian Du、Biwen Wang、Chao Wang、Jianliang Xiao、Weijun Tang

  DOI：10.1016/j.cclet.2020.09.011

  日期：2021.3

  achiral electron-rich mono-phosphine ligand, catalyzes efficient asymmetric hydrogenation of a wide range of aryl ketones, affording chiral alcohols with high yields and moderate to excellent enantioselectivities (29 examples, up to 93% ee). Notably, the achiral mono-phosphine ligand shows a remarkable effect on the enantioselectivity of the reaction.

  手性钴夹钳配合物，与非手性富电子的单膦配体结合，可催化多种芳基酮的有效不对称氢化，提供高收率和中等至优异对映选择性的手性醇（29例，最高93％ee）。值得注意的是，非手性单膦配体对反应的对映选择性表现出显着的影响。